Gutierrez Amezcua, Jose Manuel
Jain, Rajan
Kleinman, George
Muh, Carrie R.
Guzzetta, Melissa
Folkerth, Rebecca
Snuderl, Matija
Placantonakis, Dimitris G.
Galetta, Steven L.
Hochman, Sarah
Zagzag, David
Article History
Accepted: 15 October 2020
First Online: 22 October 2020
Compliance with Ethical Standards
:
: R. Jain is a consultant for Cancer Panels Inc., has received royalties from Thieme Inc., and is on the advisory board for Nuevozen Inc. D. Placantonakis has received consultant fees from Tocagen, Synaptive Medical, Monteris, and Robeaute. D. Placantonakis, D. Zagzag, and NYU Grossman School of Medicine have filed a patent application titled “Method for treating high-grade gliomas by administering GPR133 inhibitors” on the use of GPR133 as a treatment target in glioma. C. Muh holds a patent on a cerebrospinal fluid shunt. The other authors report no conflicts.
Free to read: This content has been made available to all.